scholarly journals The fulminant index: a method of rapidly differentiating fulminant type 1 diabetes from diabetic ketoacidosis

2021 ◽  
Author(s):  
Junlin Qiu ◽  
Xia Li ◽  
Wen Chen ◽  
Xiaoxi Ma ◽  
Zhiguo Xie ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Fulminant Type 1 Diabetes ◽  
Fulminant Type

Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes

2016 ◽  
Vol 53 (5) ◽  
pp. 853-856 ◽  
Author(s):  
Sung Hye Kong ◽  
Seo Young Lee ◽  
Ye Seul Yang ◽  
Tae Min Kim ◽  
Soo Heon Kwak
Keyword(s):  
Cell Death ◽  
Type 1 Diabetes ◽  
Programmed Cell Death ◽  
Diabetic Ketoacidosis ◽  
Fulminant Type 1 Diabetes ◽  
Programmed Cell Death 1 ◽  
Fulminant Type

scholarly journals Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature

2019 ◽  
Vol 12 (8) ◽  
pp. e229568 ◽  
Author(s):  
Hafez Mohammad Ammar Abdullah ◽  
Radowan Elnair ◽  
Uzma Ikhtiar Khan ◽  
Muhammad Omar ◽  
Oscar L Morey-Vargas
Keyword(s):  
Type 1 Diabetes ◽  
Diabetic Ketoacidosis ◽  
Death Receptor ◽  
Rapid Onset ◽  
Acute Onset ◽  
Fulminant Type 1 Diabetes ◽  
Life Threatening ◽  
Cell Death Receptor ◽  
Fulminant Type

Nivolumab is a programmed cell death receptor (PD-1) inhibitor that is increasingly used for various malignancies, both as a first line agent and as salvage therapy. Being a PD-1/PD-1 ligand checkpoint inhibitor, it is known to cause autoimmune inflammation of various organs and has been associated with thyroiditis, insulitis, colitis, hepatitis and encephalitis to name a few. There are increasing reports of nivolumab leading to acute onset fulminant type 1 diabetes and diabetic ketoacidosis (DKA). We present a case of a 68-year-old man who developed DKA after 2 doses of nivolumab for metastatic melanoma. He was found to have type 1 diabetes, but no diabetes related antibodies were positive. He recovered from diabetes and continues to use insulin 1 year after his diagnosis. This case and associated review illustrates the importance of educating and monitoring patients who start nivolumab therapy regarding this potentially life threatening complication.

scholarly journals Diabetic Ketoacidosis Following Colonoscopy in Fulminant Type 1 Diabetes: A Case Report

2018 ◽  
Vol 93 (2) ◽  
pp. 216-219
Author(s):  
Dug-Hyun Choi ◽  
Bo-Yeon Kim ◽  
Chan-Hee Jung ◽  
Chul-Hee Kim ◽  
Sung-Koo Kang ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Case Report ◽  
Diabetic Ketoacidosis ◽  
Fulminant Type 1 Diabetes ◽  
Fulminant Type
Sign in / Sign up

Export Citation Format

Share Document